Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
JPM: Bluebird to spin off cancer therapies into new company
JPM: Bluebird to spin off cancer therapies into new company
Fierce Biotech
Bluebird Bio
spinoffs
oncology
JPMHC 2021
Oncology Newco
Flag link:
10 Biopharma Stories to Look Forward to in 2021
10 Biopharma Stories to Look Forward to in 2021
BioSpace
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
Flag link:
3 FDA Dates Biotech Investors Should Circle in 2021
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Flag link:
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
Pharmaforum
Bluebird Bio
Zinteglo
gene therapy
beta-thalassemia
Flag link:
FDA gene therapy holdups suggest closer scrutiny by agency
FDA gene therapy holdups suggest closer scrutiny by agency
BioPharma Dive
FDA
gene therapy
Sarepta Therapeutics
Voyager Therapeutics
Iovance
Bluebird Bio
Flag link:
Can bluebird bio Recover From Another Major Setback?
Can bluebird bio Recover From Another Major Setback?
Motley Fool
Bluebird Bio
bb1111
sickle cell disease
Flag link:
FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay
FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay
Endpoints
Bluebird Bio
FDA
sickle cell disease
gene therapy
HGB-206
Flag link:
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Flag link:
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
Flag link:
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
BioPharma Dive
CRISPR
gene therapy
beta thalassemia
sickle cell disease
CRISPR Therapeutics
Vertex
Bluebird Bio
EHA
Flag link:
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EP Vantage
Bluebird Bio
sickle cell disease
LentiGlobin
EHA
Flag link:
What Sanofi Might Buy With Its Regeneron Windfall
What Sanofi Might Buy With Its Regeneron Windfall
Barron's
Sanofi
Regeneron
M&A
gene therapy
Ultragenyx
Bluebird Bio
Flag link:
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
Motley Fool
Bluebird Bio
beta thalassemia
LentiGlobin
FDA
pandemic
clinical trials
Flag link:
Biotech companies raise cash as coronavirus updates lift stocks
Biotech companies raise cash as coronavirus updates lift stocks
BioPharma Dive
biotech
biotech stocks
COVID-19
Moderna Therapeutics
Bluebird Bio
Turning Point Therapeutics
Gossamer Bio
Krystal Biotech
Clovis Oncology
Gamida Cell
Bellerophon
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Flag link:
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
Bluebird says gene therapy application delayed again, citing disagreement with FDA
Bluebird says gene therapy application delayed again, citing disagreement with FDA
BioPharma Dive
Bluebird Bio
LentiGlobin
FDA
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »